ClinicalTrials.gov
ClinicalTrials.gov Menu

Hd-bronchoscopy, Comparison to Standard White Light and Autofluorescence Bronchoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01676012
Recruitment Status : Completed
First Posted : August 30, 2012
Results First Posted : May 12, 2015
Last Update Posted : May 12, 2015
Sponsor:
Information provided by (Responsible Party):
Radboud University

Brief Summary:

Through technological improvement a new technique has become available in the form of high-definition (HD-) bronchoscopy. Current normal video white light bronchoscopy is the standard, and video-autofluorescence bronchoscopy (AFB) is offered by specialized centers only. The impact of this development with high-definition videobronchoscopy using a 1.1 megapixel chip on the diagnostic performance of bronchoscopy is however unknown.

The aim of the present study therefore is to explore the diagnostic performance (sensitivity and specificity) of HD-videobronchoscopy, HD + surface enhancement (iScan filtering technique) and HD + tone enhancement filtering in comparison to standard WLB and dual mode SAFE3000 autofluorescence videobronchoscopy in a high risk population.


Condition or disease
Cancer

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 32 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: High Definition Bronchoscopy; an Exploratory Study of Diagnostic Value in Comparison to Standard White Light Bronchoscopy and Autofluorescence Bronchoscopy
Study Start Date : September 2012
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Group/Cohort
five types of bronchoscopy

Bronchoscopy will be performed in a standardized order using five different imaging modes.

  1. Standard white light videobronchoscopy (WLB)
  2. High Definition -Bronchoscopy
  3. HD-bronchoscopy + surface enhancement (iScan-surface)
  4. HD-bronchoscopy + tone enhancement (iScan-tone)
  5. Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode



Primary Outcome Measures :
  1. Sensitivity [ Time Frame: one year ]
    Investigate sensitivity of HD bronchoscopy, with or without surface enhancement or tone enhancement in comparison to AFB (the 'gold standard') and standard WLB for detecting abnormalities of the tracheobronchial tree. So we used 5 types of bronchoscopy; SWL (=standard white light), HD (=high defenition bronchoscopy without surface/tone enhancement), HD-i-Scan1 (=high defention bronchoscopy with surface enhancement), HD-i-scan 2 (=high defenition bronchoscopy with tone enhancement), AFB (=autofluorescence bronchoscopy). Furthermore we aim to investigate determination of resection margins of (suspected) malignancies in the glottic and supraglottic area or centrally located lung cancer in comparison to autofluorescence bronchoscopy (SAFE 3000 dual video mode) in a high risk population with biopsies from all suspect lesions identified by either technique.


Secondary Outcome Measures :
  1. Sensitivity and Specificity of HD Videobronchoscopy [ Time Frame: one year ]
    When the sensitivity and specificity of HD videobronchoscopy in either mode in the abovementioned study is in the vicinity of the reported sensitivity and specificity of SAFE3000 dual mode videobronchoscopy we suggest to use the results of this study perform a power analysis. With this information it may then be possible to design a new future study to compare sensitivity for detecting premalignant lesions in a high risk population in a prospective study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with suspected or proven head and neck or lung cancer fit for surgery and scheduled for diagnostic or therapeutic surgical procedure in the Radboud University Medical Center Nijmegen
Criteria

Inclusion Criteria:

  • Patients fit for surgery and scheduled for diagnostic or therapeutic surgical procedure under general anesthesia by the cardiothoracic or thoracic surgeon or ENT surgeon with suspected or proven lung cancer or head and neck cancer.
  • ASA physical status 1-3.
  • Age 18 years or older.
  • informed consent

Exclusion Criteria:

Contraindications are all known contraindications for diagnostic bronchoscopy such as:

  • bleeding disorders,
  • indication for use of anticoagulant therapy (acenocoumarol, warfarins, therapeutic dose of low molecular weight heparins or clopidogrel),
  • known allergy for lidocaine,
  • known pulmonary hypertension,
  • recent and/or uncontrolled cardiac disease. Presence of contraindications for the use of laryngeal mask (anatomical abnormalities) increased risk for intubation (mallampati score 4), or compromised upper airway due to extension of primary head and neck cancer.

ASA classification greater than or equal to 4.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01676012


Locations
Netherlands
Radboud University Medical Center Nijmegen
Nijmegen, Geert Grooteplein 10, Netherlands, 6525 GA
Sponsors and Collaborators
Radboud University
Investigators
Principal Investigator: HFM vanderHeijden, MD Principal Investigator

Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT01676012     History of Changes
Other Study ID Numbers: 38719
First Posted: August 30, 2012    Key Record Dates
Results First Posted: May 12, 2015
Last Update Posted: May 12, 2015
Last Verified: May 2015